Cholestin status not just "Pharmanex' fight" anymore but "industry issue," Israelsen says.
This article was originally published in The Tan Sheet
Executive Summary
CHOLESTIN STATUS NOT JUST "PHARMANEX' FIGHT" BUT "INDUSTRY ISSUE," LDI Group President Loren Israelsen said at a nutraceuticals conference in New York City May 20-21. FDA's recent decision the product is an unapproved new drug is "really big" for the dietary supplement industry, which "has to take the view that this is not just Pharmanex' fight, [but that] this is now an industry issue, and we all really have to look to get involved," Israelsen urged. The conference was sponsored by the Foundation for Innovation in Medicine.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning